Nitric oxide inhalation - Novoteris

Drug Profile

Nitric oxide inhalation - Novoteris

Alternative Names: Thiolanox

Latest Information Update: 28 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novoteris
  • Developer Novoteris; University of British Columbia; University of Toronto
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cystic fibrosis
  • No development reported Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 05 Jun 2017 The US FDA and the Therapeutic Products Directorate of Health Canada approves a phase II clinical trial application for Cystic fibrosis
  • 05 Jun 2017 Novoteris plans a phase II trial for Cystic fibrosis in USA and Canada (Inhalation)
  • 22 Feb 2017 Phase-II clinical trials in Cystic fibrosis in USA (Inhalation) (NCT02498535)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top